Dimethyltryptamine boosted early graft mechanics after cold storage in a rat transplant model
Preserving donor heart function during cold ischemia remains one of the central problems in transplantation, because the first minutes after reperfusion can determine whether a graft stabilizes or slips into primary dysfunction. In this rat heterotopic heart transplantation model, dimethyltryptamine (DMT) was paired with standard Custodiol preservation and given to both donors and recipients, then tested against control grafts after one hour of cold storage at 4 °C. The readout came quickly: within 60 minutes of reperfusion, DMT-treated grafts generated stronger pressure and better contraction-relaxation performance than controls.
The study focused on an injury window that transplant teams know well. Ischemia-reperfusion injury compresses oxygen deprivation, ionic disturbance, oxidative stress, and inflammatory signaling into a short but damaging period, and the myocardium often pays for that insult immediately after blood flow returns. A compound that can soften that cascade during storage and early reperfusion has obvious biological appeal, even before the mechanism is fully mapped.
Stronger left ventricular pressure and improved relaxation emerged early
Functional assessment showed higher left ventricular systolic pressure in the DMT-treated grafts, along with better indices of contractility and diastolic relaxation. The investigators used preload-dependent pressure measurements, which matters because transplant performance at this stage is not just about force generation; it is also about whether the ventricle can relax and refill without becoming stiff or energetically inefficient. Early graft survival depends on both sides of that equation.
One sentence captures the result plainly: the DMT arm came out of reperfusion with a heart that worked better.
That improvement is especially relevant in the setting of cold ischemia, where membrane injury, calcium handling defects, mitochondrial dysfunction, and endoplasmic reticulum stress can all blunt myocardial performance at once. A graft that develops higher systolic pressure and more favorable relaxation after the same preservation interval suggests a form of cytoprotection rather than a trivial shift in measurement noise.
Stress-response genes changed, but tissue injury markers did not move in parallel
Molecular profiling showed significant modulation of Ddit3, Hif1a, and Vldlr, pointing toward altered responses in endoplasmic reticulum stress, hypoxia signaling, and lipid-related metabolism. These pathways are not random reads from a panel; each sits close to the biology of transplant injury. Ddit3 is linked to unfolded protein stress, Hif1a is a major oxygen-sensing transcriptional regulator, and Vldlr reflects shifts in metabolic handling that may matter when an organ is forced to recover under stress.
The tissue-level story was more complicated. There was a strong trend toward increased cleaved caspase-3 expression and significantly higher p62 immunohistochemical scores, while cardiac troponin I and TNF-α levels remained unchanged. In other words, the grafts performed better without a simple parallel fall in all classic markers of injury or inflammation. That pattern does not erase the functional benefit; instead, it suggests that the hemodynamic gain may be emerging through stress adaptation, altered proteostasis, or improved cellular resilience rather than through a blunt suppression of necrosis or cytokine release.
p62 accumulation can point to altered autophagic flux, and cleaved caspase-3 signals engagement of apoptotic machinery. Seeing those signals alongside better mechanical performance creates a mechanistic tension worth watching. The heart may be responding to DMT through a compensatory pathway that improves short-term performance even while parts of the stress-response network remain active.
Sigma-1 receptor biology offers a plausible route for cytoprotection
DMT was evaluated in the context of its interaction with the sigma-1 receptor, a target associated with cellular survival signaling under hypoxic and oxidative stress. That receptor biology gives the findings a plausible mechanistic frame. Sigma-1 signaling has been linked to calcium homeostasis, mitochondrial preservation, and attenuation of stress-induced cell damage, all of which are highly relevant during graft storage and reperfusion.
The organ-specific logic is straightforward. During cold preservation, the heart is not merely resting; it is accumulating metabolic strain in a low-temperature environment that slows but does not eliminate injury. When reperfusion begins, the myocardium has to re-establish membrane gradients, resume aerobic metabolism, and avoid a burst of reactive damage. If DMT can modulate the cellular response to that transition, even transiently, the early post-transplant period could become more stable.
The study design is also notable for keeping the intervention close to the transplant window. Hearts from male Lewis rats were preserved for one hour at 4 °C in either Custodiol alone or Custodiol supplemented with DMT, and donors and recipients in the treatment arm also received DMT. That approach makes the model more relevant to peri-transplant exposure than a distant preconditioning strategy alone.
A transplant signal, not a clinical answer
This work sits firmly in the experimental space. It does not establish a role for DMT in human heart transplantation, and it does not prove that the observed functional gain will translate into lower rates of primary graft dysfunction, shorter ICU stays, or better longer-term graft survival. The mechanistic readouts also leave room for interpretation, because the contractile benefit arrived without changes in cardiac troponin I or TNF-α and with a mixed apoptosis-autophagy signature.
Still, the result is hard to dismiss. In a model built to expose ischemic vulnerability, DMT improved early graft hemodynamics under the exact conditions where transplant surgeons need help most: immediately after reperfusion, when a marginal organ can either recover or fail. The data suggest a biologically active compound capable of shifting the early recovery trajectory, even if the downstream pathway remains incompletely defined.
The next step is obvious: determine whether the same signal appears in larger models, whether the effect persists beyond the first hour of reperfusion, and whether the balance of stress-response pathways can be linked to durable graft protection rather than short-lived hemodynamic improvement.